Enanta Pharmaceuticals (ENTA) Assets (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Assets came in at $314.7 million in Q1 2026, down 2.57% YoY from $323.0 million in Q1 2025, and down 4.49% on a QoQ basis from $329.5 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Assets (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Assets data on file, last reported at $314.7 million in Q1 2026.
- Quarterly Assets fell 2.57% year-over-year to $314.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $314.7 million (down 2.57% YoY) and the FY2025 annual result came in at $280.7 million, down 25.47% from the prior year.
- Assets retreated to $314.7 million in Q1 2026, from $329.5 million in the prior quarter.
- In the past five years, Assets ranged from a high of $495.2 million in Q2 2023 to a low of $280.7 million in Q3 2025.
- A 5-year average of $371.4 million and a median of $375.4 million in 2022 frame the typical range for Assets.
- Annual changes were most pronounced in 2023 — Assets climbed 28.54% — and 2025, when it retreated 25.47%.
- Tracing ENTA's Assets over 5 years: stood at $347.5 million in 2022, then advanced by 23.3% to $428.5 million in 2023, then retreated by 18.64% to $348.6 million in 2024, then decreased by 5.49% to $329.5 million in 2025, then fell by 4.49% to $314.7 million in 2026.
- The last three Assets figures came in at $314.7 million (Q1 2026), $329.5 million (Q4 2025), and $280.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 296.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 296.87 Mn |
| Mar 31, 2026 | 314.70 Mn |
| Dec 31, 2025 | 329.50 Mn |
| Sep 30, 2025 | 280.73 Mn |
| Jun 30, 2025 | 301.03 Mn |
| Mar 31, 2025 | 322.99 Mn |
| Dec 31, 2024 | 348.64 Mn |
| Sep 30, 2024 | 376.65 Mn |
| Jun 30, 2024 | 398.82 Mn |
| Mar 31, 2024 | 413.56 Mn |
| Dec 31, 2023 | 428.50 Mn |
| Sep 30, 2023 | 462.28 Mn |
| Jun 30, 2023 | 495.17 Mn |
| Mar 31, 2023 | 326.45 Mn |
| Dec 31, 2022 | 347.53 Mn |
| Sep 30, 2022 | 375.41 Mn |
| Jun 30, 2022 | 385.21 Mn |
| Mar 31, 2022 | 406.82 Mn |
| Dec 31, 2021 | 440.59 Mn |
| Sep 30, 2021 | 438.79 Mn |